Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Amy S. Clark, Igor Makhlin, Angela DeMichele
Abstract
Abstract PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance. See related articles by Lu et al., p. 408, and Tolaney et al., p. 418
Topics & Concepts
PI3K/AKT/mTOR pathwayCyclin-dependent kinaseDiscovery and development of mTOR inhibitorsPalbociclibMedicineDrug resistanceAcquired resistanceCancer researchPharmacologyBreast cancerOncologyCancerInternal medicineBiologyCell cycleSignal transductionMetastatic breast cancerBiochemistryGeneticsAdvanced Breast Cancer TherapiesChronic Lymphocytic Leukemia ResearchCancer-related Molecular Pathways